Company / PP&E (Net)
OCULAR THERAPEUTIX, INC PP&E (Net) History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest PP&E (Net)
$19.7M
FY2025
5-year range
$7.0M / $19.7M
FY2021-FY2025
Trend
+109.6%
vs FY2024
Sector context
#79 of 193
Health Care
What the data says
At $20M, OCULAR THERAPEUTIX, INC's pp&e (net) ranks #79 of 193 in the Health Care sector. PP&E (Net) has fluctuated over the past 10 years, ranging from $3M in FY2016 to $20M in FY2025.
Based on SEC 10-K filings.
$20M in FY2025 with a 5-year CAGR of +19.4%.
Improved from $12M to $20M over the past 2 years.
Health Care sector context is included.
PP&E (Net) over time
Growth rates
- 3-Year CAGR
- +25.9%
- 5-Year CAGR
- +19.4%
- 10-Year CAGR
- -
Sector benchmark
#79 of 193 in Health CareTop 41% of 193This company $19.7M Sector average $777.6M
▼
-97.5% below sector average
Key checks
Key Insights
- 5-year CAGR of +19.4%, indicating consistent growth.
- In FY2025, pp&e (net) increased 109.6% year-over-year.
- Ranks #79 out of 193 companies in the Health Care sector.
- Lowest pp&e (net) in the period was in FY2016.
Company context
Key Data Points
- Altman Z-Score 0.25 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | PP&E (Net)Value | YoY GrowthYoY |
|---|---|---|
| FY2025 | $19.7M | +109.6% |
| FY2024 | $9.4M | -20.0% |
| FY2023 | $11.7M | +19.1% |
| FY2022 | $9.9M | +41.7% |
| FY2021 | $7.0M | -14.1% |
| FY2020 | $8.1M | -20.3% |
| FY2019 | $10.2M | -0.8% |
| FY2018 | $10.2M | -2.3% |
| FY2017 | $10.5M | +216.3% |
| FY2016 | $3.3M | +7.0% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026